ALMB-0168 / CSPC Pharma 
Welcome,         Profile    Billing    Logout  

3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ALMB-0168 / CSPC Pharma
ALMB-0168 002, NCT06416358: A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed

Not yet recruiting
2
144
NA
ALMB-0168
AlaMab Therapeutics (Shanghai) Inc.
Advanced Solid Tumors With Bone Only Metastasis
06/26
12/26
ALMB-0168-CN-101, NCT04886765: A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma

Not yet recruiting
1/2
238
NA
ALMB-0168
AlaMab Therapeutics (Shanghai) Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Osteosarcoma
11/23
05/24
ChiCTR2100046224: A Phase I/II, Multi-center, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients with Osteosarcoma

Recruiting
1/2
166
 
ALMB-0168
The First Affiliated Hospital, Sun Yat-Sen University; AlaMab Therapeutics (Shanghai))Inc., Completely self-financing
Osteosarcoma
 
 

Download Options